CSL Alentis Partnership: $1.6B Lixudebart Deal Explained
CSL pays $355M upfront in a partnership with Alentis to co-develop lixudebart for rare kidney and liver diseases, worth up to about $1.6B.
CSL pays $355M upfront in a partnership with Alentis to co-develop lixudebart for rare kidney and liver diseases, worth up to about $1.6B.
FDA granted HeartBeam Breakthrough Device Designation for its 3D ECG system to help physicians assess suspected heart attacks, including at home.
FDA has cleared AIRS Medical’s SwiftSight Body Composition, AI software that measures fat, muscle and liver fat from an MRI scan of under five minutes.
Axogen closed its $200 million cash purchase of BioCircuit on 1 October, adding NerveTape, an FDA-cleared sutureless nerve repair device, to its portfolio.
Everest Medicines’ application to make Velsipity locally in China won priority review; production is anticipated in 2027 at about 50 million tablets a year.
Indian insurers are weighing a 10% co-pay on hospital claims, capped at Rs 5 lakh, from 1 January 2027 in exchange for lower premiums. What it means.
Six drones hit Kusum Healthcare's Sumy plant in Ukraine, killing an engineer; co-founder Sanjeev Gupta says it could stay shut for one to two years.
AI in neurosurgery market to grow from USD 850 million in 2025 to USD 11.3 billion by 2035 (29.5% CAGR). Growth drivers, key players and regional outlook.
AI-assisted surgery market to reach USD 39.31 billion by 2035 at 26.8% CAGR. Key growth trends, leading companies and how regions compare, led by North America.
A boiler explosion at the TIL Healthcare plant in Sri City, Andhra Pradesh on 3 October left several workers dead and injured; cause under investigation.